A case of <scp>HCC</scp> successfully treated with infliximab‐steroid sequential therapy for small bowel perforation due to atezolizumab/bevacizumab combination therapy — Satoru Hagiwara (2022) | RDL Network
A case of <scp>HCC</scp> successfully treated with infliximab‐steroid sequential therapy for small bowel perforation due to atezolizumab/bevacizumab combination therapy
Article 2022 en
Authors
SH
Satoru Hagiwara
YK
Yoriaki Komeda
NN
Naoshi Nishida
Abstract
1 min read
There are no reports of gastrointestinal perforation by atezolizumab/bevacizumab for hepatocellular carcinoma, and prior administration of infliximab. We therefore report the clinical course and management.
Parissa Tabrizian, Rebecca Marino, Sherrie Bhoori, Marcus Zeitlhoefler, Neil Mehta, Vanessa Banz, Salvatore Gruttadauria, Massimo Iavarone, Chiara Mazzarelli, Nicolò Simonotti, Francis Y. Yao, Vincenzo Mazzaferro, Josep M. Llovet
Discussion(0)
No comments yet. Be the first to comment.